hybridizes, under stringent conditions, to at least one second nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the nucleotide sequences set forth as SEQ ID NOs: 1, 2, 3, 4, and 5,

- (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and
- (c) full length complements of (a) or (b), wherein the stringent conditions are hybridization at 65°C in hybridization buffer (3.5x SSC, 1x Denhardt's solution; 25 mM sodium phosphate buffer (pH 7.0), 0.5% SDS, 2mM EDTA), wherein SSC is 0.15M sodium chloride/0.015M sodium citrate, pH7; wherein SDS is sodium dodecyl sulphate, and EDTA is ethylenediaminetetraacetic acid.
- 37. (Twice Amended) A composition of matter useful in stimulating an immune response to at least one protein encoded by at least one nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, said composition comprising a plurality of immunogenic peptides derived from the amino acid sequence of at least one of the said proteins, wherein said peptides bind to one or more MHC molecules presented on the surface of cells.

Remarks

Applicants have amended claim 6 to remove the word "associated" from the phrase "cancer associated antigen". Claim 6 has also been amended to include the high stringency conditions for hybridization in the claim. Support for the amendment can be found in the specification at least at page 13, lines 17-20, which incorporates by reference the high stringency hybridization conditions taught in U.S. Patent No. 5,342,774. Claim 37 has been amended to include the word "immunogenic" to more clearly describe the metes and bounds of the claimed invention. Support for the amendment can be found at least at page 14, lines 11-13 of the specification. Claim 37 has also been amended to remove the phrase "which express an abnormal amount of said at least one protein". No new matter has been added.